BIOMAT Database Logo BIOMAT Database Logo

Multidrug resistance analysis in lymphoproliferative disease of large granular lymphocytes. 1998

T Lamy, and B Drenou, and O Fardel, and L Amiot, and I Grulois, and P Y Le Prise, and T P Loughran, and R Fauchet
Department of Hematology-Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida 33612, USA.

Multi-drug resistance (MDR) phenotype contributes to the ineffectiveness of chemotherapy. P-glycoprotein (PgP) and lung resistance protein (LRP) are proteins implicated in chemoresistance. We analysed the expression of PgP and LRP respectively in 17 and 15 cases of lymphoproliferative disease of granular lymphocytes (LDGL) including 10 cases of clonal large granular lymphocytic (LGL) leukaemia, six cases of oligoclonal (n = 5) and polyclonal (n = 1) CD3+ lymphoproliferation and one case of CD3- NK lymphocytosis. Functional PgP activity, as determined by Rh123 dye efflux assay, was found in all the patients. The mean percentage of effluxing cells was 47 +/- 22%, compared to 35 +/- 8% on normal lymphocytes (P<0.04). The efflux was blocked in the presence of verapamil, a PgP revertant agent. A high proportion of CD57+ cells (66 +/- 10%) from these patients expelled Rh123. Functional PgP activity was associated with expression of MDR1 mRNA. By using immunocytochemistry, LRP expression was detected in 11/15 patients (73%). 7/10 LGL leukaemia patients presented a LRP+/Efflux+ phenotype and 5/7 had LRP+/Efflux+/MDR1 mRNA+ phenotype. These findings suggest that the PgP+/LRP+ phenotype is frequently observed in LDGL. Its clinical relevance in aggressive cases remains to be determined.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008232 Lymphoproliferative Disorders Disorders characterized by proliferation of lymphoid tissue, general or unspecified. Duncan's Syndrome,X-Linked Lymphoproliferative Syndrome,Duncan Disease,Epstein-Barr Virus Infection, Familial Fatal,Epstein-Barr Virus-Induced Lymphoproliferative Disease In Males,Familial Fatal Epstein-Barr Infection,Immunodeficiency 5,Immunodeficiency, X-Linked Progressive Combined Variable,Lymphoproliferative Disease, X-Linked,Lymphoproliferative Syndrome, X-Linked, 1,Purtilo Syndrome,X-Linked Lymphoproliferative Disease,X-Linked Lymphoproliferative Disorder,Disease, Duncan,Disease, X-Linked Lymphoproliferative,Diseases, X-Linked Lymphoproliferative,Disorder, Lymphoproliferative,Disorder, X-Linked Lymphoproliferative,Disorders, Lymphoproliferative,Disorders, X-Linked Lymphoproliferative,Epstein Barr Virus Induced Lymphoproliferative Disease In Males,Epstein Barr Virus Infection, Familial Fatal,Familial Fatal Epstein Barr Infection,Immunodeficiency 5s,Immunodeficiency, X Linked Progressive Combined Variable,Lymphoproliferative Disease, X Linked,Lymphoproliferative Diseases, X-Linked,Lymphoproliferative Disorder,Lymphoproliferative Disorder, X-Linked,Lymphoproliferative Disorders, X-Linked,Lymphoproliferative Syndrome, X-Linked,Lymphoproliferative Syndromes, X-Linked,Purtilo Syndromes,Syndrome, Purtilo,Syndrome, X-Linked Lymphoproliferative,Syndromes, Purtilo,Syndromes, X-Linked Lymphoproliferative,X Linked Lymphoproliferative Disease,X Linked Lymphoproliferative Disorder,X Linked Lymphoproliferative Syndrome,X-Linked Lymphoproliferative Diseases,X-Linked Lymphoproliferative Disorders,X-Linked Lymphoproliferative Syndromes
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D005260 Female Females
D006098 Granulocytes Leukocytes with abundant granules in the cytoplasm. They are divided into three groups according to the staining properties of the granules: neutrophilic, eosinophilic, and basophilic. Mature granulocytes are the NEUTROPHILS; EOSINOPHILS; and BASOPHILS. Granulocyte
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

T Lamy, and B Drenou, and O Fardel, and L Amiot, and I Grulois, and P Y Le Prise, and T P Loughran, and R Fauchet
The lymphoproliferative disease of large granular lymphocytes.
January 1991, Acta haematologica Polonica,
T Lamy, and B Drenou, and O Fardel, and L Amiot, and I Grulois, and P Y Le Prise, and T P Loughran, and R Fauchet
Chronic lymphoproliferative disease of large granular lymphocytes.
January 1988, Neoplasma,
T Lamy, and B Drenou, and O Fardel, and L Amiot, and I Grulois, and P Y Le Prise, and T P Loughran, and R Fauchet
Lymphoproliferative disease of granular lymphocytes.
May 1995, Journal of the American Academy of Dermatology,
T Lamy, and B Drenou, and O Fardel, and L Amiot, and I Grulois, and P Y Le Prise, and T P Loughran, and R Fauchet
Indolent lymphoproliferative disease of large granular lymphocytes after lung transplantation.
May 1999, Haematologica,
T Lamy, and B Drenou, and O Fardel, and L Amiot, and I Grulois, and P Y Le Prise, and T P Loughran, and R Fauchet
[Granular lymphocyte-proliferative disorders, lymphoproliferative disease of granular lymphocytes].
January 2000, Ryoikibetsu shokogun shirizu,
T Lamy, and B Drenou, and O Fardel, and L Amiot, and I Grulois, and P Y Le Prise, and T P Loughran, and R Fauchet
Lymphoproliferative disease of "LAK cell" precursor large granular lymphocytes in association with celiac disease.
June 1993, American journal of hematology,
T Lamy, and B Drenou, and O Fardel, and L Amiot, and I Grulois, and P Y Le Prise, and T P Loughran, and R Fauchet
Exercise-induced variations of lymphocytosis in the lymphoproliferative disease of large granular lymphocytes.
September 1992, British journal of haematology,
T Lamy, and B Drenou, and O Fardel, and L Amiot, and I Grulois, and P Y Le Prise, and T P Loughran, and R Fauchet
Lymphoproliferative disorder of granular lymphocytes. A heterogeneous disease.
March 1992, Archives of pathology & laboratory medicine,
T Lamy, and B Drenou, and O Fardel, and L Amiot, and I Grulois, and P Y Le Prise, and T P Loughran, and R Fauchet
DNA microarray analysis of T cell-type lymphoproliferative disease of granular lymphocytes.
August 2002, British journal of haematology,
T Lamy, and B Drenou, and O Fardel, and L Amiot, and I Grulois, and P Y Le Prise, and T P Loughran, and R Fauchet
[Lymphoproliferative diseases of granular lymphocytes].
June 1991, Haematologica,
Copied contents to your clipboard!